» Articles » PMID: 24857068

Progress in the Treatment of Advanced Prostate Cancer

Overview
Specialty Oncology
Date 2014 May 27
PMID 24857068
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The androgen receptor (AR) is the most significant target for patients with metastatic castration-resistant prostate cancer (mCRPC). There is now irrefutable evidence that the AR axis is functional in most patients throughout the history of prostate cancer, is crucial from diagnosis to death, even in patients who have received hormonal manipulation, and represents a relevant therapeutic target in all phases of the disease. The potential mechanisms of tumor escape after castration are multifold, with each mechanism today representing a therapeutic opportunity. Phase III trials have been able to demonstrate improved overall survival (OS), improved quality of life, decreased skeletal-related events, and other important clinical benefits in young and elderly patients. After the initial positive results with docetaxel chemotherapy in improving OS, further research has resulted in five new treatments in the past few years. Immunotherapy with sipuleucel-T, cabazitaxel chemotherapy, the androgen biosynthesis inhibitor abiraterone acetate, the antiandrogen enzalutamide, and the radioisotope radium-223 have all been shown to improve OS in large-scale, well-conducted clinical trials. Proper understanding of mechanisms of resistance and of cross-resistance among these agents, sequencing, and combinations is now a priority.

Citing Articles

IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer.

Leslie A, Ning S, Armstrong C, DAbronzo L, Sharifi M, Schaaf Z iScience. 2024; 27(2):108984.

PMID: 38327800 PMC: 10847745. DOI: 10.1016/j.isci.2024.108984.


Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.

Yehya A, Ghamlouche F, Zahwe A, Zeid Y, Wakimian K, Mukherji D Cancer Drug Resist. 2022; 5(3):667-690.

PMID: 36176747 PMC: 9511807. DOI: 10.20517/cdr.2022.15.


Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.

Verma S, Prajapati K, Kushwaha P, Shuaib M, Singh A, Kumar S Cancer Drug Resist. 2022; 3(4):742-761.

PMID: 35582225 PMC: 8992566. DOI: 10.20517/cdr.2020.45.


Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study.

Fennessy F, Fedorov A, Vangel M, Mulkern R, Tretiakova M, Lis R Acad Radiol. 2019; 27(10):1432-1439.

PMID: 31862185 PMC: 7297658. DOI: 10.1016/j.acra.2019.10.017.


Further application of hyperbaric oxygen in prostate cancer.

Lu Q, Li X, Ouyang J, Li J, Chen G Med Gas Res. 2019; 8(4):167-171.

PMID: 30713670 PMC: 6352573. DOI: 10.4103/2045-9912.248268.